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Diabetic retinopathy (DR) remains the leading cause of 
blindness among working-age individuals in developed coun-
tries. Current treatments for DR are indicated in too advanced 
stages of the disease and are associated with significant 
adverse effects. Therefore, new pharmacological treatments 
for the early stages are needed.
DR has been classically considered a microcirculatory 
disease of the retina. However, increasing evidence suggests 
that retinal neurodegeneration is an early event in the patho-
genesis of DR that predates and participates in the micro-
circulatory abnormalities that occur in DR [1-6]. In fact, we 
have found the main features of retinal neurodegeneration 
(apoptosis and glial activation) in retinas from diabetic donors 
with mild or even without any microcirculatory abnormality 
appearing in ophthalmologic examinations performed during 
the year before death [7-9].
Diabetes increases apoptosis in neurons, especially in 
the inner retina, where retinal ganglion cells (RGCs) are 
located [6]. This loss of neural cells results in a reduction 
in the thickness of the retinal nerve fiber layer, which has 
been detected in rats with streptozotocin (STZ) diabetes and 
in clinical studies using scanning laser polarimetry [10] or 
optical coherence tomography [11,12]. This thinning of the 
ganglion cell layer has also been found in diabetic patients 
without or with only minimal DR [11-13]. In several experi-
mental models of diabetic retinopathy, activation of death 
receptors and mitochondrial damage by oxidative and endo-
plasmic reticulum stressors are major triggers of apoptosis 
that ultimately lead to cellular damage [14-17]. However, 
little is known regarding the activation of these signaling 
pathways in the neuroretinas of diabetic patients. Research 
on the molecular mechanisms involved in apoptosis of the 
neuroretina could facilitate the design of new therapies aimed 
at preventing or ameliorating the progression of DR at early 
stages. Accordingly, in the present study we evaluated key 
molecules that regulate proapoptotic and survival signaling in 
the neuroretinas of diabetic patients in the early stages of DR.
METHODS
Human samples: Five human post-mortem eyes were obtained 
from five consecutive type 2 diabetic donors between March 
2011 and January 2012. All ocular tissues were used in 
accordance with applicable laws and with the Declaration of 
Helsinki for research involving human tissue. In addition, this 
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Purpose: Diabetic retinopathy (DR) has been classically considered a microcirculatory disease of the retina. However, 
before any microcirculatory abnormalities can be detected in ophthalmoscopic examination, retinal neurodegeneration is 
already present. The aim of the study was to analyze proapoptotic and survival signaling in the neuroretinas of diabetic 
patients at early stages of DR.
Methods: The retinas from five diabetic donors at early stages of DR were compared with the retinas from five non-
diabetic donors matched by age. Glial activation was evaluated by assessing glial fibrillar acidic protein (GFAP) with 
western blot and immunofluorescence. Proapoptotic molecules (FasL, procaspase-8, active caspase-8, total Bid, truncated 
Bid, Bim, and active caspase-3), as well as antiapoptotic markers (FLIP, BclxL, and cyclooxygenase-2 [COX-2]) were 
assessed with western blot.
Results: GFAP and proapoptotic molecules (FasL, active caspase-8, truncated Bid (t-Bid), Bim, and active caspase-3) 
were significantly increased in the neuroretinas from diabetic patients compared to the control neuroretinas. In contrast, 
no significant differences in the expression of the antiapoptotic markers were found.
Conclusions: An imbalance between proapoptotic and survival signaling was found in diabetic neuroretinas. Our results 
reveal key mechanistic pathways involved in the neurodegenerative process that occurs in the early stages of DR.
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study was approved by the ethics committee of our hospital. 
The mean duration of diabetes was 8.1±3.2 years, and all 
patients had mild non-proliferative DR in ophthalmologic 
examinations performed during the preceding two years. 
The causes of death were cardiovascular disease (n=4) and 
malignant neoplasm (n=1).
Five eyecups obtained from nondiabetic donors closely 
matched by age (69.1±7.4 versus 68.3±6.5 years) were selected 
from our eye bank as the control group. In both groups, the 
time elapsed from death to eye enucleation was less than 4 h. 
After enucleation, the eyes were snap frozen at –80 °C and 
stored until assayed. The neuroretina and the retinal pigment 
epithelium (RPE) were harvested under the microscopic 
dissection of isolated eyecups from donors. Three retinal 
sections of each retina were obtained from the central area 
(around the optic nerve).
Protein extraction from human neuroretina: Protein extracts 
and tissue sections from samples of neuroretinas from diabetic 
and control individuals were prepared. Protein extracts from 
the neuroretina were prepared by homogenization with lysis 
buffer containing 50 mM Tris-HCl, 1% Triton X-100, 2 mM 
ethylene glycol-bis (beta-aminoethyl ether)-N,N,N’,N’-tetra 
acetic acid( EGTA), 10 mM EDTA acid, 100 mM NaF, 1 mM 
Na4P2O7, 2 mM Na3VO4, 100 μg/ml phenylmethylsulfonyl 
fluoride, 1 μg/ml aprotinin, 1 μg/ml pepstatin A, and 1 μg/
ml leupeptin. using the Brinkman PT 10/35 Polytron (ALT, 
East Lyme, CT). Extracts were kept ice-cold at all times. 
Extracts were cleared by microcentrifugation at 40,000 ×g 
for 20 min at 4 °C. The supernatant was aliquoted and stored 
at −70 °C. All ocular tissues were used in accordance with 
applicable laws and with the Declaration of Helsinki for 
research involving human tissue. In addition, this study was 
approved by the ethics committee of the Institut de Recerca 
Hospital Universitari Vall d’Hebron (Barcelona, Spain).
Western blotting: After sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS–PAGE) was performed, 
gels were transferred to Immobilon membranes (Millipore) 
and were blocked using 5% non-fat dried milk or 3% bovine 
serum albumin in 10 mmol/l Tris-HCl and 150 mmol/l NaCl 
pH 7.5, and incubated overnight with several antibodies in 
0.05% Tween-20, 10 mmol/l Tris-HCl, and 150 mmol/l NaCl 
pH 7.5. All primary antibodies were used at 1:1000 dilutions. 
Immunoreactive bands were visualized using the enhanced 
chemiluminescence (ECL) western blotting protocol (Milli-
pore). Anti-Bim (Ref. 559685) and anti- BclxL (Ref. 610211) 
antibodies were from BD Biosciences PharMingen (San 
Diego, CA). Anti-Bid (Ref. AF860) and anti-FLIP (Ref. 
AF821) antibodies were from R&D Systems. Anticleaved 
(Asp175) caspase-3 antibody (#9661) was purchased from 
Cell Signaling (Beverly, MA). Anticaspase-8 (sc-7890) and 
anticyclooxygenase-2 (anti-COX-2; sc-19.999) antibodies 
were from Santa Cruz Biotechnology (Palo Alto, CA). Anti-
FasL antibody (AB-16982) was from Upstate (Millipore). 
The assessment of glial fibrillar acidic protein (GFAP) with 
western blot (GFAP antibody: Ab7260, Abcam, Cambridge, 
UK) has been also described elsewhere [7]. Briefly, a total of 
5 μg protein from the neuroretina was resolved by 12% SDS-
PAGE and transferred to a polyvinylidene fluoride membrane 
(Millipore, Billerica, MA). The membranes were incubated 
with a primary antibody against human glial fibrillar acidic 
protein (GFAP), diluted 1:200,000, and further incubated 
with peroxidase-conjugated secondary antibody (Bio-Rad 
Laboratories). Proteins were visualized using the enhanced 
chemiluminescence detection system (Supersignal CL-HRP 
Substrate System; Pierce, Rockford, IL). The same blot was 
stripped and reblotted with an antibody specific to β-actin 
(Santa Cruz Biotechnology, Santa Cruz, CA) to normalize 
the GFAP levels. For densitometric analysis of western blots, 
Image J software was used.
Glial fibrillar acidic protein immunofluorescence: GFAP 
immunofluorescence in the neuroretina was performed as 
previously described [9]. Briefly, tissue sections were incu-
bated overnight at 4 °C with the primary antibody chicken 
antihuman GFAP (1:1000; Abcam). After washing, sections 
were incubated with Alexa Fluor 568 (Molecular Probes; 
Eugene, OR) secondary antibody for 1 h. GFAP immu-
nofluorescence in the neuroretina was quantified using 
laser confocal microscopy (FluoView ASW 1.4; Olympus, 
Hamburg, Germany), and the units represent the total fluo-
rescence intensity values corresponding to ten field images 
(40X NA:0.9) of each retina sample.
Transferase-mediated dUTP nick-end labeling: Apoptosis 
was analyzed with the In situ Cell Death Detection Kit 
with fluorescein isothiocyanate (FITC; Roche, Barcelona, 
Spain), which is based on transferase-mediated dUTP 
nick-end labeling reaction following the manufacturer’s 
instructions. In summary, paraffin-embedded eye sections 
(7 μm thickness) from diabetic and nondiabetic donors 
were deparaffinized with xylene and rehydrated in ethanol. 
Then, a 50 μl terminal deoxynucleotidyl transferase dUTP 
nick end labeling (TUNEL) reaction mixture was added 
to each section and incubated in a humidified atmosphere 
for 60 min at 37 °C in the dark. Images were acquired in 
a confocal laser scanning microscope (FV1000, Olympus) 
using either a 488 nm laser line for FITC or a 405 nm laser 
line for 4’,6-diamidino-2-phenylindole (DAPI). Each retinal 
section was visually scanned with a high-power lens (60X) 
that covered 212 × 212 μm of each retina. The total number 
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of TUNEL-positive cells was recorded in a masked fashion 
using the values corresponding to 15 field frame images from 
three retinal sections (five fields each). The mean value was 
then standardized (mathematically converted) to a 0.5-cm2 
area. To avoid false-positive fluorescence, a phase-contrast 
image for each field was also obtained.
Figure 1. Glial activation in 
neuroretina from diabetic patients. 
Comparison of glial fibrilllar acidic 
protein (GFAP) immunofluores-
cence (red) in the human retina 
between representative samples 
from a nondiabetic (A) and diabetic 
(B) donor. In the diabetic retina, 
the Müller cells show abundant 
GFAP immunof luorescence and 
the radial processes stain intensely 
throughout the inner and outer 
retina. ONL, outer nuclear layer; 
INL, inner nuclear layer; GCL, 
ganglion cell layer. The bar repre-
sents 20 μm. C: Quantification 
of GFAP immunofluorescence in 
nondiabetic (n=5) and diabetic 
retinas (n=5). D: Western blot anal-
ysis of neuroretinas corresponding 
to three representative diabetic 
and nondiabetic retinas. E: Densi-
tometric quantification showing 
higher GFAP in the retinas from 
five diabetic donors compared with 
the retinas from five nondiabetic 
donors. Results are expressed as 
means±SD. *p<0.001. **p=0.04.
Molecular Vision 2013; 19:47-53 <http://www.molvis.org/molvis/v19/47> © 2013 Molecular Vision 
50
Statistical analysis: Results are means±SD. Statistical 
significance was tested with a one-way analysis of variance 
followed by the protected least-significant difference test; 
p<0.05 was considered significant. In experiments using 
X-ray films, different exposure times were used to ensure 
that bands were not saturated.
RESULTS
Biomarkers of retinal neurodegeneration: As expected, the 
two main features of retinal neurodegeneration (apoptosis 
and glial activation) were present in the diabetic retinas. A 
higher intensity of GFAP immunofluorescence was detected 
in the diabetic retinas (7,450±927 versus 3,473±819, p<0.001; 
Figure 1A-B). In addition, an increase in GFAP assessed with 
western blot (arbitrary units) was observed in the neuroretinas 
from diabetic patients compared with nondiabetic indi-
viduals (1.64±1.03 versus 0.40±0.39, p=0.04; Figure 1C-D). 
Furthermore, the diabetic retinas presented a higher ratio of 
apoptosis (percentage of TUNEL positive cells per 0.5 cm2) 
than nondiabetic retinas (21±9 versus 3±1; p<0.001).
Differential proapoptotic and survival signaling in neuro-
retinas from diabetic patients and control individuals: The 
results of the proapoptotic and survival molecules measured 
in the retina from diabetic patients and nondiabetic control 
individuals are shown in Figure 2 and Figure 3. The expres-
sion of FasL, a proapoptotic component of the death receptor 
pathway, was significantly increased in the neuroretinas 
from diabetic patients compared to the control individuals. 
The interaction of FasL with the death receptor Fas/CD95 
assembles the death-inducing signaling complex (DISC) 
[18]. This includes the recruitment of caspase-8. Activation 
of caspase-8, monitored by the presence of its 20 kDa active 
fragment, was significantly increased in neuroretinas from 
diabetic patients compared to the control individuals. These 
Figure 2. Apoptotic signaling path-
ways in neuroretina from diabetic 
patients. A: Protein extracts 
were prepared from neuroretina 
from diabetic patients (n=5) and 
nondiabetic control individuals 
(n=5). Total protein (50 μg) was 
used for western blot analysis with 
the antibodies against Fas ligand 
(FasL), caspase-8, BH3 interacting-
domain death agonist (Bid), B-cell 
lymphoma 2 interacting mediator 
of cell death (Bim), and active 
caspase-3. Anti-GADPH antibody 
was used as a loading control. B: 
Autoradiograms were quantified 
with scanning densitometry. The 
results are expressed as arbitrary 
units of protein expression and are 
means±SD. *p<0.05, **p<0.01 and 
***p<0.005 diabetic patients (D) 
vsersus control individuals (C).
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data were reinforced by the detection of elevated levels of 
truncated Bid fragment (tBid) in diabetic samples. Moreover, 
the proapoptotic Bcl2 family member Bim, which is involved 
in the mitochondria-mediated intrinsic apoptotic pathway, 
significantly increased in diabetic patients compared to the 
control individuals. As a result, the neuroretinas from diabetic 
patients displayed significant activation of the executer 
caspase-3, monitored by the presence of its 15–17 kDa active 
fragment, compared to the control individuals (Figure 2). In 
contrast, no significant changes in the expression of anti-
apoptotic markers such as FLIP, a component of the DISC, 
and BclxL, an antiapoptotic member of the Bcl2 family, were 
found between the diabetic and control individuals although 
a trend toward an increase in COX-2 content in diabetic 
patients was observed (Figure 3).
DISCUSSION
In the present study, we explored the proapoptotic signaling 
pathways involved in the neurodegenerative process that 
occurs in the early stages of DR in diabetic patients. As 
occurs in other cells, the imbalance between the proapop-
totic and survival intracellular signaling pathways determines 
the extent of cellular damage in the neuroretina and, conse-
quently, is critical for the pathogenesis of DR [19]. Therefore, 
studying these pathways will permit us not only to define the 
molecules that are altered by the diabetic milieu but also to 
gain new insights into the design of therapeutic strategies.
We recently reported that stress and survival signaling 
are oppositely regulated in retinal pigment epithelia from 
diabetic patients [20], but there is no information regarding 
this issue for the neuroretina. In this study, we demonstrated 
for the first time that activation of the death receptor pathway, 
monitored by the elevation in the expression of FasL and the 
activation of caspase-8, is significantly higher in neuro-
retinas from diabetic patients than in nondiabetic control 
individuals. Importantly, our data clearly show increased 
Bid cleavage in the neuroretinas from diabetic patients. This 
result suggests that in neuroretinas from diabetic patients the 
apoptotic signals emerging from the death receptor pathway 
are amplified to additional activation of the intrinsic apop-
totic signaling pathway, resulting in stronger activation of 
the executer caspase-3. In conjunction, our results clearly 
demonstrate that targeting the activation of the Fas/FasL 
death receptor pathway might be a novel therapeutic strategy 
against DR. In light of our data, Fas was upregulated in rat 
neutrophils from streptozotocin-treated rats in parallel with a 
simultaneous increase in Fas expression in the retinal vascu-
lature, thereby resulting in apoptosis in endothelial cells [21]. 
Moreover, Al-Asrar et al. reported a histological analysis of 
human diabetic retinas showing Fas and FasL immunoreac-
tivity in ganglion and glial cells, respectively [22]. However, 
the latter report did not delineate the sequential activation of 
the molecular mediators of the Fas/FasL system in diabetic 
retinas as shown in the present study. Importantly, researchers 
recently reported that in addition to exerting death-promoting 
effects, the death receptor Fas can induce the secretion of 
inflammatory cytokines such as interleukin-6 (IL-6), IL-1β, 
IL-1α, IL-8, and monocyte chemotactic protein-1 (MCP-1) in 
different cell lines [23,24]. Thus, in addition to the activation 
Figure 3. Survival signaling path-
ways in neuroretina from diabetic 
patients. A: Protein extracts were 
prepared from neuroretina from 
diabetic patients (n=5) and nondia-
betic control individuals (n=5). 
Total protein (50 μg) was used for 
western blot analysis with the anti-
bodies against B-cell lymphoma-
extra large (BclxL), FLICE-like 
inhibitory protein (FLIP) and 
ciclooxygenase-2 (COX2). Anti-
GADPH antibody was used as a 
loading control. B: Autoradiograms 
were quantified with scanning densitometry. Results are expressed as arbitrary units of protein expression and are means±SD. C: nondiabetic 
donors, D: diabetic donors.
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of apoptosis, FasL might trigger additional inflammatory 
damage, and DR might progress, in part, as the result from 
chronic exposure of the neuroretina to proinflammatory cyto-
kines. Additional research will unravel this relevant issue.
In contrast, no differences in the expression of antiapop-
totic proteins were found between the two groups although a 
trend toward an increase in COX-2 expression was observed 
in the neuroretinas from diabetic patients, probably reflecting 
an antiapoptotic defense. Notably, all these findings were 
observed at early stages of DR.
In conclusion, an imbalance between proapoptotic and 
survival signaling was found in the neuroretinas of diabetic 
patients. Our results reveal key mechanistic pathways 
involved in the neurodegenerative process that occurs in the 
early stages of DR. The relevance of these findings should be 
interpreted in the context of identifying apoptotic markers 
that might be useful for designing new therapeutic strategies 
aimed at preventing the progression of DR.
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